Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer

Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have become the frontier of cancer treatment and successfully prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC). But the efficacy varies among different patient population, and many p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Kexun, Li, Shuo, Zhao, Yi, Cheng, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944349/
https://www.ncbi.nlm.nih.gov/pubmed/36845142
http://dx.doi.org/10.3389/fimmu.2023.1127071
_version_ 1784891895727521792
author Zhou, Kexun
Li, Shuo
Zhao, Yi
Cheng, Ke
author_facet Zhou, Kexun
Li, Shuo
Zhao, Yi
Cheng, Ke
author_sort Zhou, Kexun
collection PubMed
description Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have become the frontier of cancer treatment and successfully prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC). But the efficacy varies among different patient population, and many patients succumb to disease progression after an initial response to ICIs. Current research highlights the heterogeneity of resistance mechanisms and the critical role of tumor microenvironment (TME) in ICIs resistance. In this review, we discussed the mechanisms of ICIs resistance in NSCLC, and proposed strategies to overcome resistance.
format Online
Article
Text
id pubmed-9944349
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99443492023-02-23 Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer Zhou, Kexun Li, Shuo Zhao, Yi Cheng, Ke Front Immunol Immunology Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have become the frontier of cancer treatment and successfully prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC). But the efficacy varies among different patient population, and many patients succumb to disease progression after an initial response to ICIs. Current research highlights the heterogeneity of resistance mechanisms and the critical role of tumor microenvironment (TME) in ICIs resistance. In this review, we discussed the mechanisms of ICIs resistance in NSCLC, and proposed strategies to overcome resistance. Frontiers Media S.A. 2023-02-08 /pmc/articles/PMC9944349/ /pubmed/36845142 http://dx.doi.org/10.3389/fimmu.2023.1127071 Text en Copyright © 2023 Zhou, Li, Zhao and Cheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhou, Kexun
Li, Shuo
Zhao, Yi
Cheng, Ke
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
title Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
title_full Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
title_fullStr Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
title_full_unstemmed Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
title_short Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
title_sort mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944349/
https://www.ncbi.nlm.nih.gov/pubmed/36845142
http://dx.doi.org/10.3389/fimmu.2023.1127071
work_keys_str_mv AT zhoukexun mechanismsofdrugresistancetoimmunecheckpointinhibitorsinnonsmallcelllungcancer
AT lishuo mechanismsofdrugresistancetoimmunecheckpointinhibitorsinnonsmallcelllungcancer
AT zhaoyi mechanismsofdrugresistancetoimmunecheckpointinhibitorsinnonsmallcelllungcancer
AT chengke mechanismsofdrugresistancetoimmunecheckpointinhibitorsinnonsmallcelllungcancer

Ejemplares similares